Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours Β· Estimated delivery Aug 8 - Aug 13
The Phase 3 study evaluated orforglipron, an investigational, once-daily oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, for weight maintenance over 52 weeks after initial treatment for 72 weeks with the highest tolerated doses of Wegovy (semaglutide) or Zepbound (tirzepatide), in participants from SURMOUNT-5 who were offered the opportunity to be re-randomized to receive orforglipron or placebo
Features Multiple current output modes (50/200/500mA) Mini size External display available Safe and fast charging Specifications Input voltage: 5V Charging current: 50mA, 200mA, 500mA Limited charging voltage: 4.2V1% Working temperature: -40?~85
Adjusting injection day is possible aim for the same weekday each week and confirm changes with your clinician
SHED requires two billing cycles before a patient is eligible to cancel
There is no single GLP-1 with the fewest side effects for every patient
Most people need maintenance treatments to sustain their results, typically scheduling sessions every 2-4 weeks once they achieve their desired outcomes
